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There is currently considerable interest world-
wide in chemicals that are able to mimic
estrogens (i.e., xenoestrogens). Because it is
possible that exposure to xenoestrogens may
(and only may) lead to adverse physiologic
effects in humans and wildlife, intense efforts
are under way to identify chemicals that pos-
sess estrogenic activity. To date, no large-
scale, systematic screening of chemicals for
estrogenic activity has been conducted
(although one is planned) (1). Instead, the
estrogenic activity of some chemicals has been
discovered by accident, usually because estro-
genic effects have been observed in groups of
animals exposed to high doses or concentra-
tions of chemicals (2), or by small-scale
screening, for example, alkylphenols (3,4) and
phthalates (5,6).
The identification of many structurally
diverse chemicals possessing (usually weak)
estrogenic activity has allowed structure–
activity relationships (SARs) to be developed
[e.g., Waller et al. (7)]. To date, these mod-
els have not been used in a predictive sense
(i.e., to identify chemicals likely to have
estrogenic activity), but they have been use-
ful in identifying the major structural fea-
tures associated with estrogenic activity.
Because receptor binding is based on the
hypothesis that all active molecules interact
with the receptor site in the same or similar
mode, a similar pattern of atoms or func-
tional groups in the compounds activating
receptor sites is usually required to facilitate
recognition and binding. In the case of the
human estrogen receptor site, a ligand with a
phenolic group seems to be a common fea-
ture of most, but not all, molecules that dis-
play a substantial binding activity (8,9). On
the basis of this knowledge, we screened a
selection of commercially used phenolic
additives to assess their estrogenic activity.
Phenolic additives are used without modifi-
cation in widely different end products, and
in this respect, they differ from most phenols
that are used in the synthesis of other
organic chemicals, frequently as components
of polymeric materials. 
Materials and Methods
Selection of chemicals. We characterized the
phenolic additives by searching directories of
commercial chemicals displaying chemical
structures (10–13). The preliminary search
generated a selection of several hundred
compounds, but we reduced this number by
excluding drugs, dyes, and those phenols
used as precursor chemicals for manufactur-
ing other compounds. There were about 140
compounds remaining; we reduced this
group to 73 by investigating only com-
pounds that were available in a high-purity
form from suppliers. We confirmed the
purity of the compounds by HPLC; in the
few cases where impurities apparently
exceeded 2%, compounds were recrystal-
lized. We believe that the compounds finally
tested are a representative, but not compre-
hensive, selection of phenols that are incor-
porated without modification into a wide
range of commercially important products.
They fell into the following classes: UV
screening agents, preservatives, disinfectants,
antioxidants, and flavoring and perfumery
components. The chemicals tested are listed
in Tables 1–5.
Assessment of estrogenic activity. Details
of the yeast estrogenicity assay (including
details of the medium components) have
been previously described (14). In brief,
yeast cells transfected with the human estro-
gen receptor α (ERα) gene, together with
expression plasmids (containing estrogen
responsive elements and the lac-Z reporter
gene encoding the enzyme β-galactosidase),
were incubated in medium containing the
test chemical and the chromogenic substrate,
chlorophenol red-β-D-galactopyranoside
(CPRG). Active ligands (which bind to the
receptor) induce β-galactosidase (β-gal)
expression, and this causes the CPRG (ini-
tially yellow) to change into a red product
that can be measured by absorbance.
Stock solutions of chemicals (dissolved
in ethanol) were serially diluted in ethanol,
and 10 µL volumes were transferred to 96-
well, flat-bottom plates. After the ethanol
was allowed to evaporate to dryness, 200 µL
medium containing CPRG and yeast was
added to each well. The plates were then
incubated at 32°C for 3 days, after which
absorbance readings were made at 540 nm
using a Spectramax 340 PC plate reader
(Molecular Devices, Sunnyvale, CA). We
included 17β-estradiol (serially diluted from
1 × 10–8 M to 4.88 × 10–12 M) and solvent
controls in each assay. Each chemical was
tested at least twice. The median effective
dose (ED50) for 17β-estradiol was 2.0 ×
10–10 M ± 0.22 × 10–10 M (mean ± SE of 14
experiments). 
We determined relative potencies of test
chemicals only when the dose–response
curves were parallel to that of 17β-estradiol.
To do so, the concentration of the test
chemical required to produce a half-maximal
response (A540 between 1.7 and 2.0) was
divided by the concentration of 17β-estra-
diol required to produce the same response.
Compounds displaying a submaximal
response were compared at the 10%
response level.
Results
Tables 1–5 list the 73 phenolic additives
tested in groups according to their use,
together with a summary of the information
generated by the in vitro estrogen assay.
Thirty-two of the compounds tested dis-
played detectable estogenic activity. None
was strongly active, and the most potent was
3,000 times less active than 17β-estradiol. 
The response curves for the additives
used as sunscreens or light stabilizers are
shown in Figure 1 and are representative of
the data obtained from all of the active chem-
icals. Twenty-two of the test compounds
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produced full dose–response curves that
were parallel to that of 17β-estradiol. Ten
compounds generated submaximal response
curves, a phenomenon that has previously
been discussed (15). In some cases, submaxi-
mal response curves occured because the test
chemical was toxic to the yeast at high con-
centrations (e.g., the dose–response curves
for benzophenone-3 and benzophenone-7 in
Figure 1A), but other chemicals generated
shallower dose–response curves than 17β-
estradiol for reasons not currently under-
stood (e.g., menthyl salicylate, benzyl
salicylate, and 2-ethylhexyl salicylate; Figure
1B). Such compounds were designated as
having submaximal response in the tabulated
results and are detailed in Table 6.
Discussion
The results summarized in Tables 1–5 show
that activity has been detected in compounds
falling into four out of the five usage cate-
gories, and only those used in flavoring and
perfumery failed to display activity. The
group of compounds used to screen UV light
contained more estrogenically active com-
pounds than the other groups, and so far,
such compounds have not attracted much
comment in this context. The structural
diversity of the compounds investigated com-
plicates the interpretation of the results, but a
slightly clearer picture emerges if the active
compounds are ranked in terms of their activ-
ity. Figures 2, 3, and 4, respectively, show the
structures of phenolic additives with activities
of 1/1,000–1/10,000, 1/10,000–1/100,000,
and < 1/100,000.
The phenolic additives investigated in
this study had from one to four nonfused
aromatic rings in their structures; in some
instances heterocyclic rings were also pre-
sent. Those compounds found to be estro-
genically active had only one or two
nonfused aromatic rings in their structures,
and with very few exceptions, one of these
rings had a phenolic -OH group in a para
position to an additional substituent. The
structures of the active additives, shown in
Figures 2, 3, and 4, make the importance of
this configuration more obvious. The sub-
stituent may be an alkyl group; a chlorine
atom; a methoxy group; or an ester, ketone,
or C-C bond linking it to a second aromatic
ring. The importance of the para position of
the phenolic group is consistent with find-
ings from a study of estrogenic activity of
alkylphenolic compounds (4). The phenolic
additives that were inactive in this study
were chiefly those in which the phenolic
-OH group was in an ortho position relative
to other substituents, or where the 2,6 posi-
tions relative to the phenolic -OH group
were occupied by other substituents, for
example, additional -OH groups in the case
of the gallates and purpurogallin; bromine
atoms in the case of tetrabromobisphenol A;
or t-butyl groups in the case of 4,4´-methyl-
enebis(2,6,-di-t-butyl phenol) [Chemical
Abstracts Service (CAS) no. 118-82-1], 2,6-
di-t-butyl-4-(dimethylaminomethyl)phenol
(CAS no. 88-27-7), octadecyl- 3-(3´,5´-di-t-
butyl-4-hydroxyphenyl)propionate (CAS no.
2082-79-3), and 2,6 di-t-butylphenol. This
suggests that where the hydrophilic phenol
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Table 1. Phenolic additives used as sunscreens or light stabilizers.
Compound CAS registry no. Usage group Estrogenic activity MW
Benzophenone-1 131-56-6 1,2 1/3,000 214.2
Benzophenone-2 131-55-5 1,2 1/7,000 246.2
Benzophenone-3 131-57-7 1,2 Submax 228.3
Benzophenone-4 4065-45-6 1 ND 308.3
Benzophenone-6 131-54-4 2 Submax 274.3
Benzophenone-7 85-19-8 2 Submax 232.7
Benzophenone-8 131-53-3 1 ND 244.2
Benzophenone-12 1843-05-6 2 ND 326.5
4,4´-Dihydroxybenzophenone 611-94-4 2 1/40,000 214.2
Phenyl salicylate 118-55-8 1 1/300,000 214.2
Benzyl salicylate 118-58-1 1 Submax 228.3
Menthyl salicylate 89-46-3 1 Submax 276.4
Ethylhexyl salicylate 118-60-5 1 Submax 250.9
Triethanolamine salicylate 2174-16-5 1 ND 287.3
Resorcinol monobenzoate 136-36-7 2 1/80,000 214.2
Octrizole 3147-75-9 2 ND 323.4
2,4-Di-t-butyl-6(5-chloro-2H- 3864-99-1 2 ND 357.9
benzotriazol-2-yl)phenol
7-Hydroxycoumarin 93-35-6 1 ND 162.1
Abbreviations: CAS, Chemical Abstracts Service; MW, molecular weight; ND, not detected; Submax, submaximal
response curve; usage group 1, cosmetic sunscreen; usage group 2, light stabilizer for polymers. Estrogenic activity
shows the potency relative to 17β-estradiol. 
Table 2. Phenolic additives used as preservatives.
Compound CAS registry no. Estrogenic activity MW
Dodecylparaben 2664-60-0 ND 306 
Benzylparaben 94-18-8 1/4,000 228.2
Butylparaben 94-26-8 1/8,000 194.2
Propylparaben 94-13-3 1/30,000 180.2
Ethylparaben 120-47-8 1/200,000 166.2
Methylparaben 99-76-3 1/3,000,000 152.2
Dichlorophen 97-23-4 ND 269.1
2-Hydroxybiphenyl 90-43-7 1/2,000,000 170.2
4-Hydroxybiphenyl 92-69-3 1/10,000 170.2
Salicylic acid 69-72-7 ND 138.1
Abbreviations: CAS, Chemical Abstracts Service; MW, molecular weight; ND, not detected. 
Table 3. Phenolic additives used as disinfectants.
Compound CAS registry no. Estrogenic activity MW
Phenol 108-95-2 ND 94.1
2-Methylphenol 95-48-7 ND 108.1
4-Methylphenol 106-44-5 ND 108.1
Thymol 89-83-8 ND 150.2
Chlorothymol 89-68-9 1/400,000 184.7
4-t-Amylphenol 80-46-6 1/200,000 164.3
Carvacrol 499-75-2 ND 150.2
4-Chloro-3-methylphenol 59-50-7 1/3,000,000 142.6
4-Chloro-3,5-dimethylphenol 88-04-0 1/900,000 156.6
2,2’-Dihydroxybiphenyl 1806-29-7 ND 186.2
8-Hydroxyquinoline 148-24-3 ND 145.2
Abbreviations: CAS, Chemical Abstracts Service; MW, molecular weight; ND, not detected. 
Table 4. Phenolic additives used in flavoring and perfumery.
Compound CAS registry no. Estrogenic activity MW
Eugenol 97-53-0 ND 164.2
Isoeugenol 97-54-1 ND 164.2
Vanillin 121-33-5 ND 152.2
Ethyl vanillin 121-32-4 ND 166.2
Methyl salicylate 119-36-8 ND 152.2
Hexyl salicylate 6259-76-3 ND 222.3
Abbreviations: CAS, Chemical Abstracts Service; MW, molecular weight; ND, not detected. 
group is hindered or deactivated, the receptor
binding capability is greatly reduced. 
17β-Estradiol has a molecular weight of
272.4 and its metabolites estrone and estriol
have molecular weights of 270.4 and 288.4,
with relative activities of one-half and 1/300
that of the parent compound, but Routledge
and Sumpter (4) showed that the estrogenic
activity of alkyl phenols peaked with 4-t-
octylphenol, which has a molecular weight of
206.4. The series of phenolic additives
examined in this study display much more
structural variation than the alkyl phenols,
but there does seem to be a similar optimum
molecular weight. For example, the mean
molecular weights of compounds falling
within the three potency ranges of
1/1,000–1/10,000, 1/10,000–1/100,000, and
< 1/100,000 are 208.2, 202.9 and 166.7,
respectively. Figure 5, a scatter diagram in
which molecular weight is plotted against the
negative logarithm of the potency, shows a
trend (correlation coefficient –0.74) in which
activity diminishes as the molecular weight
decreases from an optimum range of about
200–230. Clearly this trend is consistent with
the concept of a receptor site that can accom-
modate molecules of the appropriate size,
shape, and charge distribution, but molecular
weight is a crude criterion because it does not
take into account any aspect of the shape or
charge distribution parameters. Nevertheless,
when the inactive additives are considered,
there were nine compounds that had an
unhindered phenolic -OH group para to
some other substituent; these were all found
to have molecular weights of < 164 or > 302,
which suggests that their lack of activity is
probably size related (Figure 5). There is no
apparent tendency for compounds with mole-
cular weights exceeding about 250 to display
a gradually diminishing activity. Instead there
seems to be a sharp cutoff between active and
inactive compounds, which is what might be
expected if a size-exclusion mechanism
excludes larger molecules from the estrogen
receptor site. Unfortunately, in the group of
compounds tested there were no compounds
in that crucial molecular weight region with
an unhindered phenolic -OH group para to
some other substituent.
Thus, the two most important criteria to
emerge from this study in relation to pheno-
lic additives displaying estrogenic activity
are a) having a phenol with a para configu-
ration and b) having a molecule of appropri-
ate size. Because the structural features of
commercially important phenolic additives
are so varied, it is only possible to cite a few
illustrative examples from the data. For
example, 4-hydroxybiphenyl is far more
active than 2-hydroxybiphenyl; 4,4´-dihy-
droxybiphenyl is active and 2,2´-dihydroxy-
biphenyl is inactive; and insertion of a
-CH2- or -C(CH3)2-group between the two
aromatic rings of 4,4´-dihydroxybiphenyl
[i.e., to give bis-(4-hydroxyphenyl) methane
and bisphenol A] makes virtually no differ-
ence to the activity of the resulting com-
pounds. Thymol, which has no substituent
group in the para position to the phenolic
-OH group, is inactive, whereas chlorothy-
mol, which has a chloro group in that posi-
tion, is active. 
The benzophenones present a complex
picture; this has been confirmed by Schultz et
Articles • In vitro estrogenicity of phenolic additives
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Table 5. Phenolic additives used as antioxidants.
Compound CAS registry no. Estrogenic activity MW
Gallic acid 149-91-7 ND 170.1
N-Propyl gallate 121-79-9 ND 212.2
N-Octyl gallate 1034-01-1 ND 282.3
Dodecyl gallate 1166-52-5 ND 338.4
5-t-Butyl-4-hydroxy-2-methyl- 96-69-5 ND 358.6
phenyl sulfide 
1,3,5-Tris(4-t-butyl-3-hydroxy-2,6,- 40601-76-1 ND 699.9
dimethylbenzyl)isocyanurate
N-(4-Hydroxyphenyl)stearamide 103-99-1 ND 375.6
2,2´-Methylenebis(4-methyl-6-t- 119-47-1 ND 340.5
butylphenol)
Bisphenol A 80-05-7 1/10,000 228.3
Bis(4-hydroxyphenyl)methane 620-92-8 1/9,000 200.2
2,2’-Ethylidene bis(4,6,-di-t-butyl) 35958-30-6 ND 438.7
Nordihydroguaiaretic acid 500-38-9 Submax 302.4
1,3,5-Trimethyl-2,4,6-tris (3,5-di-t- 1709-70-2 ND 775.2
butyl-4-hydroxybenzyl)benzene
4,4’-Methylenebis(2,6,-di-t- 118-82-1 ND 424.7
butylphenol)
Butylated hydroxytoluene 128-37-0 Submax 220.4
2,6-Di-t-butylphenol 128-39-2 Submax 206.4
4-t-Butylphenol 98-54-4 1/3,000,000 150.2
Catechol 120-80-9 ND 110.1
4-t-Butylcatechol 98-29-3 1/300,000 166.2
Butylated hydroxyanisole 25013-16-5 Submax 180.3
Purpurogallin 569-77-7 ND 220.3
Vitamin E 59-02-9 ND 430.8
2,6-Di-t-butyl-4-(dimethylamino- 88-27-7 ND 263.4
methyl)phenol
Octadecyl-3-(3’5’-di-t-butyl-4- 2082-79-3 ND 530.9
hydroxyphenyl)propionate
4,4’-Dihydroxybiphenyl 92-88-6 1/9,000 186.2
Tetrabromobisphenol Aa 79-94-7 ND 543.9
2,4,5-Trihydroxybutyrophenone 1421-63-2 ND 196.2
4-t-Octylphenol 140-66-9 1/5,000 206.4
Abbreviations: CAS, Chemical Abstracts Service; MW, molecular weight; ND, not detected; Submax, submaximal
response curve. 
aThis compound is a fire retardant.
Figure 1. Response of the estrogen yeast bioassay to phenolic additives used as sunscreens and UV
inhibitors. Each data point was the mean of triplicate values, and the data are representative of the overall
experimental results. 
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al. (16) in a recent study of the estrogenicity
of 18 benzophenone derivatives using a
recombinant yeast assay. Schultz et al. (16)
attempted to predict the level of estrogenicity
using certain structural rules, but few of the
compounds they examined are in use as addi-
tives. The most active compounds detected
in our own work (i.e., benzophenone-1 and
benzophenone-2) have phenolic -OH
groups in both para and ortho positions,
whereas 4,4´-dihydroxybenzophenone, hav-
ing only para -OH groups, is surprisingly
less active. Other benzophenones either pro-
duced no response or were classified as
slightly estrogenic due to submaximal
response curves, but HPLC with UV detec-
tion suggests that trace contamination with
benzophenone-1 may be responsible for the
slight activity observed in some of these com-
pounds. These other compounds only had
phenolic -OH groups in the ortho position. 
The paraben esters, which have previously
been studied in detail using the same yeast
assay (17), display a progressive increase in
estrogenic activity as the molecular weight
increases from 152.2 to 228.2. In general,
their activity was substantially greater than the
salicylate esters, which is what would be
expected because the ester group in the salicy-
late esters is in an ortho position relative to the
phenolic -OH group. The most active of the
salicylate esters studied was phenyl salicylate,
which with a molecular weight of 214.2 was
close to the mean value for the most active
group of compounds, whereas its activity level
was close to that of ethyl paraben.
This study suggests that a surprisingly
large number of chemicals in everyday use
may possess weak estrogenic activity, at least
in vitro. This contention is supported by a
preliminary announcement by Tong et al.
(18) of a very intelligent and thorough SAR-
based modeling study of the 57,000 chemi-
cals in the database of the U.S. Food and
Drug Administration. The authors suggest
that over 3,000 of the 57,000 chemicals
probably possess weak estrogenic activity (at
least in vitro). The identification of chemicals
Articles • Miller et al.
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Table 6. Estrogenic potency values (10% response level) for compounds displaying submaximal
responses.
Compound CAS registry no. Estrogenic potency
Benzophenone-3 131-57-7 1/100,000
Benzophenone-6 131-54-4 1/20,000,000
Benzophenone-7 85-19-8 1/300,000
Benzyl salicylate 118-58-1 1/600,000
Menthyl salicylate 89-46-3 1/200,000
Ethylhexyl salicylate 118-60-5 1/2,000,000
Nordihydroguaiaretic acid 500-38-9 1/600,000
Butylated hydroxytoluene 128-37-0 1/8,000,000
2,6, Di-t-butylphenol 128-39-2 1/20,000,000
Butylated hydroxyanisole 25013-16-5 1/2,000,000
CAS, Chemical Abstracts Service. 
Figure 2. Chemical structures of compounds with an activity relative to 17β-estradiol of 1/1,000 to 1/10,000.
Figure 3. Chemical structures of compounds with
an activity relative to 17β-estradiol of 1/10,000 to
1/100,000.
possessing estrogenic activity is, unfortu-
nately, only the initial step (and probably the
easiest step). This hazard assessment should
lead to risk assessment. To complete realistic
risk assessments, it is necessary to know
whether the in vitro activity (identified here)
translates into in vivo activity, and if it does,
to what degree. It is also necessary to know
the extent and route of exposure of the active
chemicals. Too often the necessary informa-
tion required to conduct a meaningful risk
assessment is incomplete. A reasonable num-
ber (perhaps a few hundred) of chemicals
have been shown to possess weak estrogenic
activity in vitro using a variety of assays. In a
few cases, some of these chemicals have
recently been investigated in vivo, sometimes
using relatively short assays, but occasionally
using multigenerational studies. For exam-
ple, the initial demonstration that some
phthalates possessed weak estrogenic activity
in vitro (5) stimulated several research groups
to investigate the possible endocrine activity
of such chemicals in vivo (19,20). Although it
is currently difficult to draw firm conclusions,
the general message seems to be that chemi-
cals are less active, but nevertheless are often
still active, in vivo than in vitro, when the
chemicals are administered orally. However,
too few chemicals have been thoroughly
tested in vivo, using appropriate assays and
end points and realistic routes of exposure, to
know the extent that endocrine activities and
potencies in vitro will be manifested in vivo.
The results mean that humans are exposed to
many different (usually weakly) estrogenic
chemicals via a number of routes. They lead
to the conclusion that there is a strong need
to understand the interactive effects of such
mixtures with endogeneous estrogens.
Conclusions
This study has shown that a substantial num-
ber of phenolic additives incorporated in a
group of different products display slight
estrogenic activity when assessed by an in vitro
yeast assay. The strongest activity is chiefly dis-
played by those compounds in which a phe-
nolic -OH group is in a para position to some
other substituents and the molecular weight
falls within the range 200–250.
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